Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.

Nan Fung Life Sciences and Novo have taken part in the immuno-oncology drug developer's series B round, which was led by Pivotal BioVenture Partners.

Pharmaceutical company Sosei has launched new companies using technology from its 2015 acquisition of Heptares, both of which have received funding from Medicxi.

Cytonus Therapeutics has spun out of UC San Diego to develop cell-based containers for the effective release of therapeutics including cancer drugs.

6 Dimensions Capital is set to exit immuno-oncology drug developer TCR² Therapeutics in an offering likely to raise between $70m and $80m.

VetMedUni biopharmaceutical spinout Marinomed Biotech has completed its IPO to attain a market cap of $109m.

The funding takes Istesso’s latest round to $13m as the company continues clinical trials on an immunometabolic drug licensed from an Aberdeen spinout in 2007.

MIT has launched an as-yet unnamed spinout to develop a smart drug-delivery pill to help plan more effective treatment regimens for patients.

US-based Blue Water Vaccines has an option on University of Oxford research into a universal influenza shot and is looking to raise $15m in funding.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.